Innovative pancreatic cancer drug approved in the US, but access is limited
The U.S. Food and Drug Administration (FDA) recently approved a new, groundbreaking drug for the treatment of metastatic pancreatic cancer. The drug, called Daraxonrasib and marketed in the U.S. under the name Rasonque, offers new hope to patients dealing with one of the most difficult diseases.
According to professional data, this is a targeted therapy that has been found to be particularly effective. Clinical trials have shown that the drug is capable of doubling the life expectancy of patients compared to currently existing treatments. This is significant news for the medical community and for many families around the world.
However, alongside the positive medical news, difficulties have arisen regarding the availability of the drug. According to reports, patients will not be able to receive the new treatment for free. The high cost of the drug raises questions regarding its accessibility for patients who need it urgently, even outside the borders of the United States.
As of now, health experts are examining the effects of the drug's approval on various healthcare systems. For patients in Israel and other countries, the central question remains whether the drug will be included in public health baskets or will remain available only to those with high financial means.
The FDA approval constitutes an important step in the global fight against cancer, but the case highlights once again the gap between advanced technological developments and the ability to make them accessible to the general public. The medical community continues to monitor further developments on this issue.